SCHEMBL19957389

SCHEMBL19957389

COCCOc1cc2nccc(Oc3ccc(NC(=S)NC4CC4)c(Cl)c3)c2cc1C(N)=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 7/20 0.72
FGFR4 P22455 7/20 0.72
KDR P35968 6/20 0.72
PDGFRA P16234 4/20 0.72
FGFR1 P11362 4/20 0.72
AURKB Q96GD4 4/20 0.72
PDGFRB P09619 3/20 0.72
KIT P10721 3/20 0.72
FGFR2 P21802 3/20 0.72
FGFR3 P22607 3/20 0.72
FLT1 P17948 2/20 0.72
FLT4 P35916 2/20 0.72
ABL1 P00519 2/20 0.72
RIPK2 O43353 1/20 0.72
ERN1 O75460 1/20 0.72
STK10 O94804 1/20 0.72
MAP3K6 O95382 1/20 0.72
ESR1 P03372 1/20 0.72
ADORA3 P0DMS8 1/20 0.72
BCR P11274 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864156 0.92 FGFR4 (0.85) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956987 0.92 KDR (0.85) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956978 0.91 FGFR4 (0.68) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956941 0.90 FGFR4 (0.66) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956957 0.89 KDR (0.79) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19957046 0.87 KDR (0.73) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19957031 0.87 KDR (0.76) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956927 0.86 KDR (0.66) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL22505669 0.86 KDR (0.64) RETFGFR4KDRPDGFRAFGFR1
SCHEMBL19956955 0.86 KDR (0.71) RETFGFR4KDRPDGFRAFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 RET 19/4885FGFR4 146/4885KDR 150/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 RET 19/4885FGFR4 146/4885KDR 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.